Intervacc AB (publ) (IVACC.ST)
SEK 0.94
(-1.37%)
SEK 0.94
(-1.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -102.85 Million SEK | -60.31% |
| 2022 | -64.15 Million SEK | -118.41% |
| 2021 | -29.37 Million SEK | -14.74% |
| 2020 | -25.6 Million SEK | 8.21% |
| 2019 | -27.89 Million SEK | -1.45% |
| 2018 | -27.49 Million SEK | -115.34% |
| 2017 | -12.76 Million SEK | -87.56% |
| 2016 | -6.8 Million SEK | -5029.58% |
| 2015 | 138.07 Thousand SEK | -98.52% |
| 2014 | 9.32 Million SEK | 508.03% |
| 2013 | -2.28 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -17.84 Million SEK | -2.62% |
| 2024 Q1 | -17.38 Million SEK | 12.53% |
| 2023 Q1 | -17.47 Million SEK | 24.18% |
| 2023 Q3 | -47.54 Million SEK | -164.82% |
| 2023 Q4 | -19.88 Million SEK | 58.19% |
| 2023 FY | -102.85 Million SEK | -60.31% |
| 2023 Q2 | -17.95 Million SEK | -2.73% |
| 2022 FY | -64.15 Million SEK | -118.41% |
| 2022 Q2 | -15.76 Million SEK | -47.02% |
| 2022 Q1 | -10.72 Million SEK | -22.88% |
| 2022 Q4 | -23.04 Million SEK | -57.7% |
| 2022 Q3 | -14.61 Million SEK | 7.32% |
| 2021 Q2 | -6.15 Million SEK | 5.03% |
| 2021 Q4 | -8.72 Million SEK | -4.97% |
| 2021 FY | -29.37 Million SEK | -14.74% |
| 2021 Q1 | -6.47 Million SEK | 8.68% |
| 2021 Q3 | -8.31 Million SEK | -35.18% |
| 2020 Q3 | -6.4 Million SEK | -10.49% |
| 2020 FY | -25.6 Million SEK | 8.21% |
| 2020 Q2 | -5.79 Million SEK | 8.19% |
| 2020 Q4 | -7.09 Million SEK | -10.81% |
| 2020 Q1 | -6.31 Million SEK | 19.62% |
| 2019 Q4 | -7.85 Million SEK | -25.88% |
| 2019 Q2 | -8.44 Million SEK | -57.54% |
| 2019 Q1 | -5.36 Million SEK | 23.45% |
| 2019 FY | -27.89 Million SEK | -1.45% |
| 2019 Q3 | -6.23 Million SEK | 26.14% |
| 2018 Q2 | -10.94 Million SEK | -152.39% |
| 2018 FY | -27.49 Million SEK | -115.34% |
| 2018 Q4 | -7 Million SEK | -34.55% |
| 2018 Q3 | -5.2 Million SEK | 52.47% |
| 2018 Q1 | -4.33 Million SEK | 34.59% |
| 2017 Q4 | -6.63 Million SEK | -186.65% |
| 2017 Q2 | -2.27 Million SEK | -46.55% |
| 2017 FY | -12.76 Million SEK | -87.56% |
| 2017 Q1 | -1.54 Million SEK | 67.84% |
| 2017 Q3 | -2.31 Million SEK | -1.88% |
| 2016 Q2 | -1.07 Million SEK | 54.21% |
| 2016 Q4 | -4.81 Million SEK | -476.69% |
| 2016 FY | -6.8 Million SEK | -5029.58% |
| 2016 Q3 | -835.44 Thousand SEK | 22.34% |
| 2016 Q1 | -2.34 Million SEK | 0.0% |
| 2015 FY | 138.07 Thousand SEK | -98.52% |
| 2014 FY | 9.32 Million SEK | 508.03% |
| 2013 FY | -2.28 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | -524.102% |
| Amniotics AB (publ) | -30.87 Million SEK | -233.178% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -701.777% |
| BioArctic AB (publ) | 229.24 Million SEK | 144.865% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 77.938% |
| Saniona AB (publ) | -95.81 Million SEK | -7.35% |
| Simris Alg AB (publ) | -37.3 Million SEK | -175.706% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 66.922% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -387.658% |
| NextCell Pharma AB | -41.95 Million SEK | -145.12% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -527.224% |
| AcouSort AB (publ) | -17.08 Million SEK | -501.861% |
| Active Biotech AB (publ) | -45.8 Million SEK | -124.568% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 58.625% |
| Camurus AB (publ) | 431.44 Million SEK | 123.839% |
| Cantargia AB (publ) | -280.02 Million SEK | 63.271% |
| Genovis AB (publ.) | 61.5 Million SEK | 267.239% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 9.24% |
| Mendus AB (publ) | -101.61 Million SEK | -1.213% |
| Kancera AB (publ) | -64.88 Million SEK | -58.505% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 2009.618% |
| LIDDS AB (publ) | -40.2 Million SEK | -155.813% |
| Lipum AB (publ) | -37.17 Million SEK | -176.647% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -748.054% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 945.197% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -474.688% |
| OncoZenge AB (publ) | -15.9 Million SEK | -546.787% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 73.503% |
| Xintela AB (publ) | -54.08 Million SEK | -90.174% |
| Ziccum AB (publ) | -21.41 Million SEK | -380.347% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -177.446% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 42.754% |
| CombiGene AB (publ) | -35.66 Million SEK | -188.38% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 32.267% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -23382.192% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -522.478% |
| Corline Biomedical AB | -1.8 Million SEK | -5585.572% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 42.166% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -81.011% |
| Aptahem AB (publ) | -11.11 Million SEK | -825.522% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 16.427% |
| Fluicell AB (publ) | -26.55 Million SEK | -287.331% |
| Biovica International AB (publ) | -124.82 Million SEK | 17.602% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -143.592% |
| Abliva AB (publ) | -95.5 Million SEK | -7.688% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 68.537% |
| 2cureX AB (publ) | -32.51 Million SEK | -216.293% |
| I-Tech AB | 20.2 Million SEK | 609.093% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 87.634% |
| Cyxone AB (publ) | -22.98 Million SEK | -347.397% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -12.528% |
| Biosergen AB | -27.03 Million SEK | -280.412% |
| Nanologica AB (publ) | -75.15 Million SEK | -36.85% |
| SynAct Pharma AB | -215.81 Million SEK | 52.341% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -133.468% |
| BioInvent International AB (publ) | -330.3 Million SEK | 68.861% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -333.298% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 58.712% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -935.769% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 5.889% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -780.733% |